#Epclusa

The Epclusa and Mavyret combination pills are now indicated for kids as young as age 3.

Despite limited testing and clinical visits, 95% of the study population was able to achieve a sustained virological response.

A rundown of POZ’s reporting on the 2020 Conference on Retroviruses and Opportunistic Infections

The assurance arrives as the pharma giant cuts off most emergency access to remdesivir, a potential COVID-19 treatment.

Six weeks, compared with the standard 12 weeks, was associated with an unacceptably high rate of viral relapse.

The first meta-analysis to examine hep C treatment outcomes in seniors versus non-seniors found that cure rates are comparable.

The drug can quickly reverse opioid-driven overdoses.

A recent study of people in British Columbia found, however, that people who inject drugs had lower cure rates.

A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco

The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.

Additionally, in a recent study, having hep C mutations associated with resistance didn’t affect the outcome of treatment.

Highlights from research presented at the 52nd International Liver Congress in Amsterdam